Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors

PURPOSE: Mutant KRAS is a major driver of pancreatic oncogenesis and therapy resistance, yet KRAS inhibitors are lacking in the clinic. KRAS requires farnesylation for membrane localization and cancer-causing activity prompting the development of farnesyltransferase inhibitors (FTIs) as anti-cancer...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Kazi, Aslamuzzaman, Xiang, Shengyan, Yang, Hua, Chen, Liwei, Kennedy, Perry, Mohamed, Ayaz, Fletcher, Steven, Cummings, Christopher, Lawrence, Harshani, Beato, Francisca, Kang, Ya’an, Kim, Michael P., Delitto, Andrea, Underwood, Patrick, Fleming, Jason B., Trevino, Jose, Hamilton, Andrew D., Sebti, Said M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6774803/
https://ncbi.nlm.nih.gov/pubmed/31227505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3399
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados